TTK Healthcare quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	233	204	+14.6%
EBITDA	3.7	5.3	−29.8%
EBITDA margin	1.6%	2.6%	−1.0 pts
Profit before tax	268	21.3	+1,158.1%
Net profit	223	20.4	+993.7%
EPS	₹157.80	₹14.43	+993.6%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	233	258	218	209	204	226	190	205	198	208	181	184	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	18.7	16.8	17.8	17.4	19.0	17.9	18.7	17.8	17.7	17.0	16.1	15.9
	252	274	236	227	223	244	209	223	216	225	197	200
	67.4	61.2	51.5	51.4	48.0	49.6	49.6	46.7	49.7	49.4	44.7	37.3
	46.9	55.1	53.3	54.0	48.8	47.0	48.1	44.3	48.9	45.6	40.2	52.6
	−0.7	−2.2	1.4	−7.7	1.0	5.2	−10.2	7.1	−8.7	−1.5	−0.9	−4.3
	46.4	46.6	41.0	41.7	41.1	41.3	36.4	38.4	37.7	38.4	32.2	32.3
	0.6	0.5	0.6	0.7	0.8	0.8	0.9	0.8	0.7	0.9	0.9	0.2
	2.2	2.1	2.1	2.2	2.2	2.2	2.2	2.1	2.0	2.1	3.3	3.3
	69.5	82.0	59.8	62.8	59.3	80.6	54.5	60.6	62.7	69.1	52.4	60.6
	232	245	210	205	201	227	181	200	193	204	173	182
	3.7	14.7	11.0	7.1	5.3	2.7	12.0	7.7	8.2	6.9	12.4	5.3
	1.6	12.6	8.9	4.9	3.1	0.5	9.8	5.6	6.2	4.9	9.1	2.0
Profit
	19.7	28.9	26.0	21.7	21.3	17.7	27.6	22.6	23.2	21.0	24.2	17.7
	248	0.0	3.5	−7.6	0.0	0.0	−5.9	0.0	0.0	19.8	0.0	0.0
	268	28.9	29.5	14.1	21.3	17.7	21.8	22.6	23.2	40.8	24.2	17.7
	44.7	7.6	7.5	4.4	0.7	4.7	5.4	5.9	6.0	9.4	5.9	5.1
	0.3	−0.0	0.3	−0.8	0.2	0.0	0.2	0.0	0.0	−0.1	0.1	−0.3
	45.0	7.6	7.8	3.6	0.9	4.7	5.6	5.9	6.0	9.2	6.0	4.8
	223	21.3	21.8	10.5	20.4	13.0	16.1	16.7	17.2	31.6	18.3	12.9
	223	21.3	21.8	10.5	20.4	13.0	16.1	16.7	17.2	31.6	18.3	12.9
	−1.8	3.4	−2.2	−0.3	0.2	0.6	−5.6	−1.0	1.3	1.9	−2.0	−0.6
	221	24.6	19.6	10.2	20.6	13.6	10.5	15.8	18.5	33.5	16.3	12.3
Per share
	₹157.80	₹15.06	₹15.40	₹7.45	₹14.43	₹9.20	₹11.43	₹11.84	₹12.17	₹22.35	₹12.93	₹9.13
	₹157.80	₹15.06	₹15.40	₹7.45	₹14.43	₹9.20	₹11.43	₹11.84	₹12.17	₹22.35	₹12.93	₹9.13
Other comprehensive income — detail
	−1.8	3.4	−2.2	−0.3	0.2	0.6	−5.6	—	—	—	—	—
	−1.8	3.5	−1.9	−0.4	0.2	0.6	−6.6	−1.2	1.7	2.0	−2.3	−0.7
	−0.1	0.1	0.3	−0.0	0.0	0.0	−1.0	—	—	—	—	—
	—	—	—	—	—	—	—	−0.2	0.4	0.1	−0.3	−0.1
	—	—	—	—	—	—	—	0.0	0.0	0.0	−2.3	12.3
	—	—	—	—	—	—	—	0.0	0.0	0.0	0.3	0.0
Per share — as-filed variants
	₹157.80	₹15.06	₹15.40	₹7.45	₹14.43	₹9.20	₹11.43	₹11.84	₹12.17	₹22.35	₹12.93	₹9.13
	₹157.80	₹15.06	₹15.40	₹7.45	₹14.43	₹9.20	₹11.43	₹11.84	₹12.17	₹22.35	₹12.93	₹9.13
Regulatory disclosures — filed alongside, not part of the P&L
	22.2	—	14.4	—	22.0	—	15.8	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	120	143	112	112	106	125	103	107	109	114	97.1	98.3
	51.3%	55.7%	51.3%	53.4%	51.9%	55.0%	54.0%	52.1%	54.7%	55.0%	53.6%	53.5%
Adjusted (ex-exceptional items) — derived
	19.7	28.9	26.0	21.7	21.3	17.7	27.6	22.6	23.2	21.0	24.2	17.7
	248	0.0	3.5	−7.6	0.0	0.0	−5.9	0.0	0.0	19.8	0.0	0.0
	16.4	21.3	19.2	16.2	20.4	13.0	20.5	16.7	17.2	16.3	18.3	12.9
	₹11.62	₹15.06	₹13.57	₹11.46	₹14.43	₹9.20	₹14.51	₹11.84	₹12.17	₹11.52	₹12.93	₹9.13

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

TTKHLTCARE₹980.00

TTK Healthcare Limited

· Others

Annual Quarterly₹ CrorePeersDCMSHRIRAM BALMLAWRIE GODREJIND 3MINDIAMcap ₹1,385 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	183.8	181.1	207.9	198.5	204.7	190.4	226.4	203.6	209.3	218.0	257.6	233.4
Other Income	15.9	16.1	17.0	17.7	17.8	18.7	17.9	19.0	17.4	17.8	16.8	18.7
Total Income	199.8	197.1	224.9	216.2	222.6	209.0	244.4	222.6	226.7	235.8	274.4	252.1
Expenses
+ Cost of Materials Consumed	37.3	44.7	49.4	49.7	46.7	49.6	49.6	48.0	51.4	51.5	61.2	67.4
+ Purchases of Stock-in-Trade	52.6	40.2	45.6	48.9	44.3	48.1	47.0	48.8	54.0	53.3	55.1	46.9
+ Changes in Inventories	-4.3	-0.9	-1.5	-8.7	7.1	-10.2	5.2	1.0	-7.7	1.4	-2.2	-0.7
+ Employee Benefit Expense	32.3	32.2	38.4	37.7	38.4	36.4	41.3	41.1	41.7	41.0	46.6	46.4
+ Finance Costs	0.2	0.9	0.9	0.7	0.8	0.9	0.8	0.8	0.7	0.6	0.5	0.6
+ Depreciation & Amortisation	3.3	3.3	2.1	2.0	2.1	2.2	2.2	2.2	2.2	2.1	2.1	2.2
+ Other Expenses	60.6	52.4	69.1	62.7	60.6	54.5	80.6	59.3	62.8	59.8	82.0	69.5
Total Expenses	182.1	172.9	203.9	193.0	200.0	181.4	226.7	201.3	205.1	209.7	245.5	232.4
EBITDA	5.3	12.4	6.9	8.2	7.7	12.0	2.7	5.3	7.1	11.0	14.7	3.7
EBIT	2.0	9.1	4.9	6.2	5.6	9.8	0.5	3.1	4.9	8.9	12.6	1.6
Profit
PBT before Exceptional Items	17.7	24.2	21.0	23.2	22.6	27.6	17.7	21.3	21.7	26.0	28.9	19.7
+ Exceptional Items	0.0	0.0	19.8	0.0	0.0	-5.9	0.0	0.0	-7.6	3.5	0.0	248.2
Pretax Income	17.7	24.2	40.8	23.2	22.6	21.8	17.7	21.3	14.1	29.5	28.9	267.9
+ Current Tax	5.1	5.9	9.4	6.0	5.9	5.4	4.7	0.7	4.4	7.5	7.6	44.7
+ Deferred Tax	-0.3	0.1	-0.1	0.0	0.0	0.2	0.0	0.2	-0.8	0.3	-0.0	0.3
Tax Expense	4.8	6.0	9.2	6.0	5.9	5.6	4.7	0.9	3.6	7.8	7.6	45.0
Net Income	12.9	18.3	31.6	17.2	16.7	16.1	13.0	20.4	10.5	21.8	21.3	223.0
+ Net Income — Continuing Ops	12.9	18.3	31.6	17.2	16.7	16.1	13.0	20.4	10.5	21.8	21.3	223.0
+ Other Comprehensive Income	-0.6	-2.0	1.9	1.3	-1.0	-5.6	0.6	0.2	-0.3	-2.2	3.4	-1.8
Total Comprehensive Income	12.3	16.3	33.5	18.5	15.8	10.5	13.6	20.6	10.2	19.6	24.6	221.2
Per Share
Basic EPS	9.13	12.93	22.35	12.17	11.84	11.43	9.20	14.43	7.45	15.40	15.06	157.80
Diluted EPS	9.13	12.93	22.35	12.17	11.84	11.43	9.20	14.43	7.45	15.40	15.06	157.80
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-5.6	0.6	0.2	-0.3	-2.2	3.4	-1.8
+ Items NOT to be Reclassified to P&L	-0.7	-2.3	2.0	1.7	-1.2	-6.6	0.6	0.2	-0.4	-1.9	3.5	-1.8
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-1.0	0.0	0.0	-0.0	0.3	0.1	-0.1
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	-0.3	0.1	0.4	-0.2	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	12.3	-2.3	0.0	0.0	0.0	—	—	—	—	—	—	—
Comprehensive Income — Non-controlling Interests	0.0	0.3	0.0	0.0	0.0	—	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	9.13	12.93	22.35	12.17	11.84	11.43	9.20	14.43	7.45	15.40	15.06	157.80
Diluted EPS — Continuing Operations	9.13	12.93	22.35	12.17	11.84	11.43	9.20	14.43	7.45	15.40	15.06	157.80
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	15.8	—	22.0	—	14.4	—	22.2
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	98.3	97.1	114.4	108.6	106.7	102.9	124.6	105.7	111.7	111.8	143.4	119.7
Gross Margin %	53.46	53.61	55.01	54.73	52.12	54.03	55.03	51.93	53.36	51.28	55.66	51.28
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	17.7	24.2	21.0	23.2	22.6	27.6	17.7	21.3	21.7	26.0	28.9	19.7
− Exceptional Items (reconciliation)	0.0	0.0	19.8	0.0	0.0	-5.9	0.0	0.0	-7.6	3.5	0.0	248.2
Net Income Adj (tax-effected)	12.9	18.3	16.3	17.2	16.7	20.5	13.0	20.4	16.2	19.2	21.3	16.4
EPS Adj	9.13	12.93	11.52	12.17	11.84	14.51	9.20	14.43	11.46	13.57	15.06	11.62
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

TTK Healthcare Q2 FY27 results (July–September 2026)

Filed with NSE on Friday, 30 October 2026 at 1:16 pm IST

TTK Healthcare (NSE: TTKHLTCARE) reported its Q2 FY27 results (July–September 2026) on Friday, 30 October 2026 at 1:16 pm IST. Consolidated net profit was ₹223 crore, up 993.7% from ₹20.4 crore in Q2 FY26 and up 947.8% from ₹21.3 crore in Q1 FY27. Revenue from operations was ₹233 crore, up 14.6% year on year and down 9.4% from the previous quarter.

Q2 FY26 results (a year earlier): 17 October 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹223 Cr+993.7% vs Q2 FY26+947.8% vs Q1 FY27
Revenue from operations: ₹233 Cr+14.6% vs Q2 FY26−9.4% vs Q1 FY27
Operating margin (EBIT): 0.7%−0.9 pts vs Q2 FY26−4.2 pts vs Q1 FY27EBIT ₹1.6 Cr
EBITDA: ₹3.7 Cr−29.8% vs Q2 FY26−74.6% vs Q1 FY27margin 1.6%
Earnings per share (basic): ₹157.80+993.6% vs Q2 FY26+947.8% vs Q1 FY27
Net profit margin: 95.5%+85.5 pts vs Q2 FY26+87.3 pts vs Q1 FY27

Questions

What was TTK Healthcare's net profit in Q2 FY27?

Consolidated net profit was ₹223 crore, up 993.7% from ₹20.4 crore in Q2 FY26 and up 947.8% from ₹21.3 crore in Q1 FY27.

How were TTK Healthcare's Q2 FY27 results?

Both grew from a year earlier: net profit was up 993.7% at ₹223 crore and revenue was up 14.6% at ₹233 crore. The operating margin was 0.7%, down 0.9 percentage points from 1.5% a year earlier. Against Q1 FY27, net profit was up 947.8% and revenue down 9.4%.

What is TTK Healthcare's net profit margin?

TTK Healthcare's net profit margin was 95.5% in Q2 FY27 (net profit as a share of revenue from operations), against 10.0% in Q2 FY26 (up 85.5 percentage points). For FY26 as a whole it was 7.7%.

What was TTK Healthcare's revenue in Q2 FY27?

Revenue from operations was ₹233 crore, up 14.6% year on year and down 9.4% from the previous quarter.

What was TTK Healthcare's EPS in Q2 FY27?

Basic earnings per share were ₹157.80, against ₹14.43 in Q2 FY26.

What was TTK Healthcare's revenue in FY26?

Revenue from operations was ₹857 crore in FY26 (April 2025–March 2026), up 7.0% from ₹801 crore in FY25. It was ₹753 crore in FY24 and ₹725 crore in FY23: up 18.2% over three years, 5.7% a year on average.

What was TTK Healthcare's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹1.6 crore, a margin of 0.7%, against 4.9% in Q1 FY27 and 1.5% in Q2 FY26. EBITDA was ₹3.7 crore, 1.6% of revenue.

What was TTK Healthcare's net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹244 crore, up 631.6% from ₹33.4 crore in the same months a year earlier. Revenue from operations was ₹491 crore, up 14.2%.

What was TTK Healthcare's net profit in FY26?

Consolidated net profit was ₹65.7 crore in FY26 (April 2025–March 2026), down 19.6% from ₹81.7 crore in FY25. It was ₹62.8 crore in FY24 and ₹640 crore in FY23: down 89.7% over three years, an average fall of 53.2% a year.

How has TTK Healthcare's profit changed over the last four quarters?

Net profit by quarter: ₹10.5 crore in Q3 FY26, ₹21.8 crore in Q4 FY26, ₹21.3 crore in Q1 FY27 and ₹223 crore in Q2 FY27. That is ₹277 crore over the four quarters, up 317.3% from ₹66.3 crore in the four quarters before. Revenue from operations: ₹209 crore, ₹218 crore, ₹258 crore and ₹233 crore.

When did TTK Healthcare announce its Q2 FY27 results?

On Friday, 30 October 2026 at 1:16 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 17 October 2025.

When will TTK Healthcare announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these TTK Healthcare figures come from?

From TTK Healthcare's own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 30 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.